Drugs / iHSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03728322 | Jan 2019 → Jan 2020 | beta thalassemia | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iHSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03728322 ↗ |
| Route | Intravenous | “iHSCs intravenous injection” NCT03728322 ↗ |